Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25616531 | 0.87 | FFAR3 (0.50) | FFAR3NPSR1LMNAMEN1KMT2A | |
| SCHEMBL25616533 | 0.87 | FFAR3 (0.50) | FFAR3NPSR1LMNAMEN1KMT2A | |
| SCHEMBL8175853 | 0.87 | FFAR3 (0.50) | FFAR3NPSR1LMNAMEN1KMT2A | |
| SCHEMBL283125 | 0.87 | — | — | |
| SCHEMBL15564880 | 0.81 | FFAR3 (0.40) | FFAR3NPSR1LMNAMEN1KMT2A | |
| SCHEMBL17958 | 0.80 | NPSR1 (0.52) | FFAR3NPSR1LMNAMEN1KMT2A | |
| SCHEMBL16786489 | 0.80 | FFAR3 (0.43) | FFAR3NPSR1LMNAMEN1KMT2A | |
| SCHEMBL1928676 | 0.80 | — | — | |
| SCHEMBL17893308 | 0.80 | FFAR3 (0.43) | FFAR3NPSR1LMNAMEN1KMT2A | |
| SCHEMBL17893499 | 0.80 | FFAR3 (0.43) | FFAR3NPSR1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368625-A1 | PIPERAZINES | Grünenthal GmbH (DE) | 2025-12-04 | — | — | US | disclosed |
| EP-4611747-A1 | IMIDAZOLE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | Genep Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024097171-A1 | IMIDAZOLE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | GENEP INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| WO-2012025857-A1 | CYCLOALKYL METHOXYBENZYL PHENYL PYRAN DERIVATIVES AS SODIUM DEPENDENT GLUCOSE CO TRANSPORTER (SGLT2) INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012025857-A1 | CYCLOALKYL METHOXYBENZYL PHENYL PYRAN DERIVATIVES AS SODIUM DEPENDENT GLUCOSE CO TRANSPORTER (SGLT2) INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | FFAR3 4180/4885NPSR1 4626/4885LMNA 4392/4885 |
| US-20250368625-A1 | PIPERAZINES | SSTR4, SSTR5, SSTR2 | FFAR3 72/4885NPSR1 6/4885LMNA 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.